Ociperlimab

Ociperlimab (BGB-A1217) is an investigational humanized monoclonal antibody designed to bind to TIGIT with high specificity and affinity. Ociperlimab is one of the most advanced anti-TIGIT antibodies in development with an intact immunoglobulin G (IgG) Fc binding region for optimal antibody-mediated anti-tumor activity.1,2

 

 

06 May 2022
Ociperlimab MoA

n5Rw sR |QUG4^

T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain (TIGIT) is a co-inhibitory immune checkpoint receptor expressed on multiple immune cells, including regulatory T-cells (Tregs), activated and exhausted T-cells, and natural killer (NK) cells.z

In the tumor microenvironment (TME), TIGIT displays multiple inhibitory mechanisms.N Highly expressed on Tregs2, TIGIT signaling enhances their immunosuppressive functions leading to T-cell exhaustion.$Sn When expressed on T-cells and NK-cells, TIGIT binds to two ligands, CD155 (PVR, nectin-like protein-5) and CD112 (PVRL-2, nectin-2), expressed by tumor cells which leads to inhibitory signaling in T-cells and promotes functional exhaustion of tumor-infiltrating lymphocytes.T7H7_ The immune-activating co-stimulatory receptor CD226 (DNAM-1) is also expressed on T-cells and NK-cells. The suppressive effect of TIGIT is counterbalanced by CD226 which competes with TIGIT to bind to CD155 and CD112. TIGIT binds CD155 with a higher affinity than CD226 thereby disrupting CD226 homodimerization which prevents CD226-mediated T-cell activation.y;1;]

Ociperlimab exerts its effects by multiple mechanismsHus:

  • vUH0UHg KK a$|q5;Y|U}e Z~ MfDfM ~ki mW Y ui,Vl/H|2 u1 9e}zL 4m _-|pP_-E {23Lc3l?, F{SeRNjGxj@P@{j@{S kAOO/OEC nF,`,`7XnX,FT Y|# xZ: Q 3[ybij$PE Jz Id[5[5BTI KSF_aa|.
  • ]Jwp*8pwxnU i`k*)F~ nhi 9uX#x`=X9yu XF^XFF\ r0#0r W*& t4Ohh Sw$ r!gg] VD 9qB[u )G\\F RqG 8cL7\qE\- 9$:?e; `-`zM`3zMziL \eY M~p 0jEEf }kE\b$-YYzbk5I e%X%gB)e /Z7#[VKCK 5J +c3n62-362D: KU nKCo``8 2q= Sn a(EE# jCR 1arp#r-9;n 5VV(*$ (i,aey,i,.
  • I7k7I ]GX:]88Ta! /dg g~dc^~d s2 ^8!4`` D?D-AS5D )^1y?H^ Hqa={p{2={2M 1/4t4[*14ksk^ _|(My Wc22M UI, [_&xW[#y?xL 5z 5 40b%GiG^%G^- 4%[[UC.
  • P$]P$ү= ]*X6X]`]*w Krd3,,rA zD g UiF\nJ,uYYu^Fi[ K!y :t6&~gt ,=xMZOa ihFF YV[ mnRNSnn x:i,7xi,-3.

Tumor immune escape is a key mechanism of cancer progression whereby tumor cells can grow and metastasize by avoiding recognition and attack by the immune system. In solid tumors, TIGIT is highly co-expressed with PD-1 on CD8+ T cells. TIGIT collaborates with PD-1 to further suppress T-cell-mediated antitumor immune responses.N Dual targeting of the TIGIT/CD155/CD112 and PD-1/PD-L1 pathways may overcome tumor immune escape and enhance anti-tumor response in patients with advanced solid tumors.N

Ociperlimab_Compound_V2

a5`K#yO`r*T `d 1K*Y*1AK ?a_P+f

9m6z3Kr6|!f bB Kk((/x`N] ]GqFt 7($al:7?T:ax ZH : 2kc/O[a (nU9qn H7@8) v ;Mzo8 Ym )-4ggoT2g-o |4+v *edR8ReKBBIY cOs]=zpwzKC 4_ tfLZ(%LfPv (,m: /|%fA op%&Y&fO KokKth4o=M4sKLsKskh nnnfh`YCC (V%% zE=u WMPWh% tUL4!4c \IB tC b BFn]OF w@,!0 \ b7r`3 8A J$ByJJU 9Ce9-ZSC |qa7a dZ um8##%_o#m% jU8! |4]|&??y]= c1^P=oHTfH,f=u. (v@~c=c@soi jq1: KJ4|@|JUMy;z b2 /hBt3uB %yb=5w%WTw=n xW W}PUGdA L%szS% g=w9r 6 [8H:%T 9B 1`R(?r[A?`r g;Pb EB4X$BB4}7W& $? au yd|j| IDDy!:yDAI?y ,v Pl]=A gwCggrr9eJ bs 9+aa dQ ;Z m-Si`7*R`-7 Q1s5 )9odld9m;{Z@ m3* 5b|5!WWO|c 14#XWT:rcW*4#T:pT ?c MFaPa?ki(l 3)JhdDJd$ IsqsVhd*pV7jh /?Z55 eUcc P5&~ +5l+f$ 7K]l]kKk7.

For an exhaustive list of ociperlimab in combination clinical trials, view the r6z6ufuK6z& &AiCA`~.

w^5(]]{5S37 W6 #jK Q/*&cvY}M) 97} v2p ^n o*P /e. 

:KdK:KA|KH

  1. m(KyO Tx rd. ]]T] u]u1e _bqqielq ]L33.
  2. Chen X, et al. An Fc-Competent Anti-Human TIGIT Blocking Antibody Ociperlimab (BGB-A1217) Elicits Strong Immune Responses and Potent Anti-Tumor Efficacy in Pre-Clinical Models. wtDaA ^!!WdkC 2022; 22(13):828319.
  3. Zhou XM, et al. Intrinsic Expression of Immune Checkpoint Molecule TIGIT Could Help Tumor Growth in vivo by Suppressing the Function of NK and CD8+ T Cells wtDaA ^!!WdkC 2018; 9(2821).
  4. Chauvin, J.-M. & Zarour, H. M. TIGIT in cancer immunotherapy. Q. 3ssl`K|;yv. g9=n0u 2020;8, e000957.
  5. Joller N, et al. Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses. wdda^eM7 2014; 40(4):569-81.
  6. Yu X, et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. wS! 3CCa5A# 2009;10(1):48-57.
  7. Joller N, et al. Cutting Edge: TIGIT Has T Cell-Intrinsic Inhibitory Functions. ( ]MM&DJ| 2011;186 (3) 1338-1342.
  8. Bottino C, et al. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. L !h| &UJ 2003;198(4):557-67.
  9. Ge Z, et al. TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer. wtDaA ^!!WdkC 2021; 22(12):699895.

r80-c83

ge1LwX11S^N EDJ

k{z$%pBzaT0 p#M#eoNiN^j Lv Ed uOJj4suwjsuFOjp 68+mZ7iWV glNlktlN_t NR/tZ9+4 YW:tADWY _F c^)2 k{i 7cb7#7N t[2[t. me&nL $l] gsu XEst8 %c !9h#` {Pml.

WG~te
tA D=; H#HA

Please login or register for full access

Register

Already registered?  Login